Surgery for paediatric cataract entails increased glaucoma risk

Article

Paediatric cataract surgery, particularly when performed in patients under the age of nine months, entails a substantial risk of post-surgical glaucoma, according to a study published in the January 2008 issue of Investigative Ophthalmology and Visual Science.

Paediatric cataract surgery, particularly when performed in patients under the age of nine months, entails a substantial risk of post-surgical glaucoma, according to a study published in the January 2008 issue of Investigative Ophthalmology and Visual Science.

Birgitte Haargaard of Glostrup University Hospital, Denmark and colleagues performed a retrospective chart review of paediatric cataract patients (n=595; eyes=946) aged 0–17 years who underwent surgery in Denmark between 1977 and 2001.

Forty-eight patients (72 eyes) developed glaucoma subsequent to surgery for paediatric cataract. Of these, patients under the age of nine months at the time of surgery were 7.2 times more likely than older patients to develop glaucoma. In these early surgery patients, at ten years after surgery, 31.9% of patients had developed glaucoma; for late surgery patients, this was 4.1%.

As age appeared to be the only statistically significant risk factor in the analysis, the researchers concluded that paediatric cataract surgery, particularly early surgery, increases the risk of glaucoma for patients and that, because glaucoma may take up to ten years to present, careful and prolonged monitoring of IOP in these patients is necessary.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.